Low Incidence of Amyloid Related Imaging Abnormalities over 104 Weeks in a Phase 2 Study of Amyloid Anti‐Oligomer Agent ALZ‐801: Phase 2 Study Results in Biomarker Positive APOE4 Carriers with Early Alzheimer’s Disease (AD)
Patrick Kesslak, Martin Tolar(Alzheimer's Association), Niels D. Prins, Joyce Suhy(BioClinica (United States)), Jerome Barakos(Sutter Health), Jakub Hort(Charles University), Aidan Power, Luc Bracoud(BioClinica (United States)), Susan Abushakra(Framingham State University), John A. Hey(Framingham State University)
Cited by 0
Related Papers
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
|JAMA Neurology|2021|602
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
|The Lancet Neurology|2012|512
Antibiotics, gut microbiota, and Alzheimer’s disease
|Journal of Neuroinflammation|2019|444